Biodesix to Report First Quarter 2025 Financial Results on May 13, 2025

Rhea-AI Summary

Biodesix (Nasdaq: BDSX), a diagnostic solutions company, has scheduled its first quarter 2025 financial results announcement for May 13, 2025, after market close. The company will host a conference call and webcast at 4:30 p.m. Eastern Time on the same day.

Key details of the earnings call:

• Financial results cover the quarter ended March 31, 2025
• Management will provide a general business update
• Analysts can participate in Q&A through a dedicated link
• Participants should join 15 minutes before start time
• Webcast replay will be available on investor website approximately two hours after call completion

LOUISVILLE, Colo., April 29, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced that it will release financial results for the first quarter ended March 31, 2025 after the close of trading on Tuesday, May 13. Biodesix management will host a conference call and webcast to discuss its financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day.

Listeners can register for the webcast via this link. Analysts who wish to participate in the question and answer session should use this link. A replay of the webcast will be available via the company’s investor website approximately two hours after the call’s conclusion. Participants are advised to join 15 minutes prior to the start time.

About Biodesix

Biodesix is a leading diagnostic solutions company, driven to improve clinical care and outcomes for patients. Biodesix Diagnostic Tests, marketed as Nodify Lung® Nodule Risk Assessment and IQLung™ Cancer Treatment Guidance, support clinical decisions to expedite personalized care and improve outcomes for patients with lung disease. Biodesix Diagnostic Development Services enable the world’s leading biopharmaceutical, life sciences, and research institutions with scientific, technological, and operational capabilities that fuel the development of diagnostic tests, tools, and therapeutics. For more information, visit biodesix.com.

Trademarks: Biodesix, Biodesix Logo, Nodify Lung, and IQLung are trademarks or registered trademarks of Biodesix, Inc.

Note Regarding Forward-Looking Statements

This press release may contain forward-looking statements that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements contained in this press release other than statements of historical fact, are forward-looking statements. The words “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “plan,” “expect,” “predict,” “potential,” “opportunity,” “goals,” or “should,” and similar expressions are intended to identify forward-looking statements. Such statements are based on management’s current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors. Biodesix has based these forward-looking statements largely on its current expectations and projections about future events and trends. These forward-looking statements are subject to a number of risks, uncertainties, and assumptions. Forward-looking statements may include information concerning the impact of backlog and the timing and assumptions regarding collection of revenues on projections, availability of funds and future capital including under the term loan facility, the anticipated impact and benefits of new clinical data, reimbursement coverage and research partnerships, and the impact of a pandemic, epidemic, or outbreak, including the COVID-19 pandemic, on Biodesix and its operations and financial performance. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. The Company's ability to continue as a going concern could cause actual results to differ materially from those contemplated in this press release and additionally, other factors that could cause actual results to differ materially from those contemplated in this press release can be found in the Risk Factors section of Biodesix most recent annual report on Form 10-K, filed March 1, 2024 or subsequent quarterly reports on Form 10-Q during 2024, if applicable. Biodesix undertakes no obligation to revise or publicly release the results of any revision to such forward-looking statements, except as required by law. Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement.

Media:
Natalie St. Denis
Natalie.StDenis@biodesix.com
(720) 925-9285

Investors:
Chris Brinzey
chris.brinzey@icrhealthcare.com
(339) 970-2843

FAQ

When will Biodesix (BDSX) release Q1 2025 earnings?

Biodesix (BDSX) will release its first quarter 2025 financial results after market close on Tuesday, May 13, 2025.

What time is Biodesix (BDSX) Q1 2025 earnings call?

Biodesix's Q1 2025 earnings conference call and webcast is scheduled for 4:30 p.m. Eastern Time on May 13, 2025.

How can investors join Biodesix (BDSX) Q1 2025 earnings call?

Investors can register for the webcast through a link provided by the company. Analysts who want to participate in Q&A should use a separate dedicated link.

Will Biodesix (BDSX) Q1 2025 earnings call be available for replay?

Yes, a replay of the webcast will be available on Biodesix's investor website approximately two hours after the call ends.

What should participants know about joining Biodesix (BDSX) Q1 earnings call?

Participants should join the call 15 minutes before the 4:30 PM ET start time on May 13, 2025.